Background. Cavitation is a serious consequence of tuberculosis. We tested the hypothesis that repetitive exposure to the same total bacterial burden of Mycobacterium tuberculosis drives greater lung destruction than a single exposure. We also tested whether inhibition of endogenous matrix metalloproteinase-1 (MMP-1) may inhibit cavitation during tuberculosis.
Tuberculosis (TB) is a major cause of morbidity and mortality, with 10.4 million new cases of TB and 1.4 million deaths in 2015 [1] . Individuals with extensive lung disease develop a spectrum of gross lesions including diffuse inflammation, tubercles, caseous tubercles, and cavities. The most consequential of these lesions is the lung cavity.
Cavities are not specific to TB, but they are the greatest risk factor for transmission of bacilli [2] [3] [4] [5] . Cavitary TB is also more difficult to treat than noncavitary TB and is associated with the emergence of drug resistance [6] . For patients with cavitary TB who are cured, the cavities may remain, offering a niche for other opportunistic infections [7] . Cavitary lesions that do resolve are associated with fibrotic scarring and chronically diminished pulmonary function [8, 9] .
A perfect storm of pathologic features coincides within cavities to drive transmission and a reduced likelihood of treatment success. The interior surface of the cavity wall represents an immune sanctuary that permits high levels of extracellular bacterial proliferation [6, 10] . Moreover, cavities often communicate with the conducting airways of the lung, providing a physical conduit for aerosolization and transmission of Mycobacterium tuberculosis bacilli [11] . Finally, diminished vascularity and widespread necrosis within the cavity wall reduce the penetration of chemotherapeutic drugs [12] [13] [14] [15] .
Despite the importance of cavities to the natural history of TB, the mechanism of cavity formation in TB remains unclear. Histologically, cavities are thought to arise from necrotic granulomas, whose centers are both devoid of extracellular matrix. Pulmonary extracellular matrix is composed primarily of collagen and elastin, which provide mechanical support to the lung while maintaining compliance and elasticity. The expression of collagenases leads to caseation, suggesting that matrix depletion may be an early mechanistic driver of cavitation [16] [17] [18] . Indeed, increased expression of collagenases is also associated with cavity formation in both animal models and patients with TB [19, 20] .
A limitation to studying TB cavitation is the lack of reproducible animal models. Mice and guinea pigs rarely develop cavities, whereas they do occur in nonhuman primate and rabbit models [21] [22] [23] . Previous studies employed presensitization with heat-killed tubercle bacilli together with a high-dose aerosol challenge, transthoracic challenge, or intrabronchial instillation [24] [25] [26] . While these methods result in cavitation in some animals, they also generate extensive pneumonitis, making it difficult to monitor granuloma formation, necrosis, and progression to cavity formation.
Here we describe a novel rabbit model for cavitary TB based on repetitive aerosol exposure. This model reliably generates multiple cavitary foci in 60%-80% of study animals in a short period of time. Compared with single exposures of the same total bacterial burden, repetitive exposure generated more advanced disease and more cavitary foci, suggesting that repetitive exposure to aerosolized bacilli may be an important determinant for the severity of TB in high-incidence settings. Coincidentally, the number of exposures experienced by newly infected TB patients was recently reported as a risk factor for disease progression [27] . We also confirmed that this model develops human-like TB cavities where matrix depletion was a pathologic feature of cavity development. Finally, we applied this model to screen cipemastat, a potent inhibitor of matrix metalloproteinase-1 (MMP-1), as a targeted inhibitor and therapeutic agent to limit TB cavitation [28, 29] .
METHODS

Infection of Rabbits
All procedures involving live animals were conducted in accordance with protocols approved by the Institutional Animal Care and Use Committee at the Johns Hopkins University School of Medicine. Female New Zealand White rabbits (2.5-3.5 kg) were purchased from Robinson Services (Mocksville, North Carolina) and housed individually in a Biosafety Level 3 facility without cross-ventilation. Rabbits were infected in a Madison aerosol droplet generation chamber (College of Engineering Shops, University of Wisconsin, Madison). The aerosol inoculum for the chamber was prepared by dilution of log-phase bacterial culture of M. tuberculosis H 37 Rv to the appropriate optical density (OD) for each experimental group.
Cipemastat Dosing
Cipemastat was obtained from the Roche Corporation (Basel, Switzerland), and the identity of the compound was confirmed by liquid chromatography-mass spectrometry.
Rabbits in the treatment group were given 100 mg/kg cipemastat orally by body weight, adjusted weekly using PediaSure as a vehicle. The concentration of cipemastat in the vehicle was 100 mg/mL. Cipemastat treatment and vehicle shams were administered daily during study weeks 5-10.
Pharmacokinetic Analysis of Cipemastat in Plasma
Three rabbits were given a single 100 mg/kg oral dose of cipemastat. Peripheral blood samples were collected every 30 minutes, then at 4, 6, 8, 12 , and 24 hours.
Experimental samples were analyzed in tandem with a standard curve prepared in untreated rabbit plasma. Plasma concentrations of cipemastat were detected and quantified by liquid chromatography-tandem mass spectrometry (AB SCIEX QTRAP 5500). Liquid chromatography was carried out by reverse-phase gradient elution between 90% mobile phase A (0.1% formic acid in water) and 95% mobile phase B (100% acetonitrile) over 2 minutes on a ZORBAX Eclipse Plus C18 column (2.1 × 50 mm, 3.5 μm, Agilent Technologies, part number 9597432-902). Selected ion monitoring of the cipemastat parent ion at m/z 437.2 identified daughter ions at m/z 262.2 and 404.3. These transitions were supported by predicted masses in a cipemastat fragmentation map and agree with transitions identified by Hopfgartner et al [30] .
Cipemastat concentration in eluate was measured as the area under the curve for mass transition peaks. Analysis was conducted using Analyst (SCIEX) and companion software MultiQuant (SCIEX). Pharmacokinetic (PK) analysis of total drug exposure over time (AUC 0-24 ), half-life (T 1/2 ), concentration maximum (C max ), and time of concentration maximum (T max ) were calculated using 2-compartment first-order PK analysis with WinNonlin software (version 7.0, Pharsight Corp).
Computed Tomography Scans
Rabbits were imaged using a CereTom 8-slice clinical computed tomography (CT) scanner with a 32.5-cm bore diameter (NeuroLogica, Boston, Massachusetts). To achieve reconstructions in the absence of motion artifact, rabbits underwent breath-holding during CT scans as described by Kübler [31] .
Identification of Cavities From CT Reconstructions
CT reconstructions were viewed using VivoQuant software (Invicro). Lung cavities were radiologically identified from CT scan reconstructions as a contiguous set of volume elements (voxels) whose size is defined by the limit of resolution of the CT scanner, within the lungs, with densities close to air (-1000 to 910 Hounsfield units [HU] ) and encapsulated by consolidation, defined as a continuous region of voxels with densities similar to water (-725 to 1000 HU). This radiological definition was consistent with the consensus definition for cavities advanced by Gadkowski and Stout [2] .
Contiguous airspace and consolidation regions were selected by connected thresholding in the density range for each landmark. Continuity of consolidation around the airspace was confirmed by eye.
Lung Extraction and Fixation
After 14 weeks, rabbits were sedated and euthanized. Lungs were removed and photographed and then gently infused with intratracheal 10% neutral buffered formalin and fixed for 48 hours.
Gross images were obtained using a Nikon D3200 digital camera and a Nikon NIKKOR lens and analyzed with ImageJ to identify the areas of visually diseased lung as a fraction of the total area of splayed lung [32] . This fraction was used as an estimate of the percentage of diseased lung.
Histology and Trichrome Quantification
Transverse lung slices were collected for paraffin embedding and histologic sectioning. Serial 5 μm sections were stained using hematoxylin and eosin, Masson's trichrome stain, or the acid-fast stain. Image capture for semiquantitative trichrome quantification was performed on a Nikon Eclipse 90i microscope with attached Nikon DS-Ri1 color camera, and analyzed using NIS Elements Advanced Research software (Nikon Instruments, Melville, New York). Regions of interest (ROI) included the full thickness of the cavity wall while excluding necrotic debris and air space at the cavity interior. Positive staining was calculated as a percentage of the total ROI.
Substrate Cleavage Assay
Recombinant human MMP-1 (BioVision, Milpitas, California) was added to a solution of type I collagen (Thermo Fisher Scientific, Waltham, Massachusetts) in phosphate-buffered saline at a molar ratio of 1:5. One hundred microliters of Novex Zymogram 1X Developing Buffer (Thermo Fisher Scientific, Waltham, Massachusetts) with or without 1 μg cipemastat was added to this solution prior to incubation at 37°C for 24 hours. At 24 hours, an equal volume of ethylenediaminetetraacetic acid was added to stop the cleavage reaction, and the products were briefly boiled and subjected to sodium dodecyl sulfatepolyacrylamide gel electrophoresis on a Mini-Protean TGX precast gel (Bio-Rad, Hercules, California).
RESULTS
Repetitive Aerosol Exposure to M. tuberculosis Causes a High Frequency of Cavitation in a Rabbit Model
Previous investigations suggested that sensitization with heatkilled mycobacteria prior to infection increased the frequency and severity of cavitation in rabbit models [26, 31] . We reasoned that multiple aerosol challenges with virulent M. tuberculosis would provide a robust sustained immune-sensitizing effect while simultaneously antagonizing both the innate and adaptive defenses.
To test this hypothesis, we conducted a limited-power study by exposing rabbits to M. tuberculosis in 2 different patterns.
For our studies, we defined exposure as the product of the bacterial concentration in the aerosol inoculum and the total time spent in the aerosol chamber. One group of rabbits received 5 aerosol challenges with M. tuberculosis at a constant exposure to inoculum at a concentration of 0.05 measured by optical density at a wavelength of 600 nm (OD 600 ) spread evenly over a 2-week period. A second group of rabbits received a single aerosol challenge with M. tuberculosis where the aerosol exposure was OD 600 0.25, 5 times that of the repetitive exposure ( Figure 1A ). These challenges corresponded to an extrapolated day 1 bacterial implantation of 400 colony-forming units (CFUs) per exposure in the OD 0.05 group and 2200 CFUs per exposure in the OD 0.25 group (Supplementary Figure 1) . We confirmed that the cumulative exposure was the same for both groups by measuring the CFUs in the aerosol inoculum ( Figure 1A) . To address the possibility that the infection chamber does not achieve aerosol concentrations of bacilli that are linearly correlated with the OD of the aerosol inoculum, we performed a titration assay to compare the OD of the aerosol inoculum with the day 1 implantation of bacteria in rabbit lungs, and showed a linear correlation in the OD range used in these experiments (Supplementary Figure 1) . Indeed, our data indicate that it is likely that repetitive exposure rabbits were infected on every occasion of exposure, as bacteria were recovered from the lungs of all rabbits in the lowest OD exposure group of our chamber titration experiment (Supplementary Figure 1) .
We monitored rabbits using CT scans. These data showed that 75% (3 of 4) of the animals in the repetitive exposure group experienced at least 1 cavity vs 25% (1/4) of the animals in the single exposure group ( Figure 1B) . Of those animals that developed cavities, those in the repetitive exposure group showed a trend toward more cavities per animal than those in the single exposure group ( Figure 1C) . On week 10 of the experiment, the rabbits were killed and the lungs were fixed. Semiquantitative gross pathologic analysis showed that rabbits in the repetitive aerosol group experienced worse lung disease than those in the single exposure group ( Figure 1D and Supplementary Figure 2) . In light of the limited number of rabbits involved in this study, these data suggest that repetitive exposure caused an increase in the severity of disease as well as the frequency and severity of cavities. cavitation as the weeks before the greatest frequency of cavitation. To study the dynamics of cavity formation generated by repetitive exposure to M. tuberculosis, we infected 8 rabbits using the repetitive exposure protocol and observed their lungs using CT scans at weeks 3, 6, 8, and 16. The overall frequency of cavitation in this study was 87% (7/8), further supporting our previous observations with the repetitive exposure method (Figure 2A ). The greatest increase in the frequency of cavitation occurred between weeks 6 and 8, during which time the frequency of cavitation among rabbits increased from 11% (1/8) at week 6 to 50% (4/8) at week 8 ( Figure 2A ). Between week 8 and week 16, the frequency of cavitation increased modestly to 63% (5/8), but was marked by occasional resolution of existing cavities and the generation of new cavities. Cavity morphology over time was observed by CT scan reconstructions. We used density segmentation analysis to identify cavities as air-filled spaces that were not connected to the bronchial tree. From this analysis, we identified 3 patterns of change in cavity morphology: (1) cavity growth ( Figure 2B and 2C, examples 1, 2, and 3); (2) cavity shrinkage ( Figure 2B and 2C, examples 2 and 3); and (3) cavity resolution ( Figure 2B and 2C, example 4). Together, these data demonstrate that cavities most often formed between 6 and 8 weeks after the initial aerosol exposure and were persistent though dynamic structures between weeks 8 and 16 of the study.
Histologic Observations Support the Hypothesis That Central Necrosis and Matrix Depletion Are Prerequisites for Cavitation
A large body of historic literature, in addition to our own observations, suggests that TB cavities arise from necrotic granulomas. As we had not previously worked with a model that generates cavities by repetitive exposure to M. tuberculosis, we investigated whether the pathologic phenotype of lung destruction was similar to human disease. Histology samples collected from rabbits infected by repetitive exposure displayed many of the microscopic findings described in TB pathology reports ( Figure 3A) [10, 21, 33, 34] . These hallmarks included granulomas, necrotic granulomas, and cavities. Histologic observations from the repetitive exposure model show that the cytoarchitecture between necrotic granulomas and cavities was similar, further supporting a close relationship between the 2 lesions ( Figures 3A, 3B, and 4C) .
The cavities generated by repetitive exposure were marked by large proliferations of acid-fast bacteria along their inner surface and a wall enriched with fibrosis ( Figure 3B ). Because our investigations are predicated on the pathologic observation that matrix depletion predisposes to cavitation, we also confirmed that collagen matrix depletion was a hallmark of cavitary lesions from repetitive exposure (Figure 4 ). These observations show that repetitive aerosol exposure in rabbits generates a spectrum of histologic lesions commonly observed in TB pathology studies and validates the model for our studies by showing that pathologic matrix depletion is modeled by rabbits following repetitive aerosol infection.
The Collagenase MMP-Inhibitor Cipemastat Is Orally Bioavailable in
Rabbits and Reaches Therapeutic Concentrations in the Peripheral Blood
We previously showed that MMP-1 transcripts accumulated in the areas near M. tuberculosis-induced lung damage, suggesting that MMP-1 activity might drive tissue destruction in TB [19] . We hypothesized that if MMP-1 was the major driver of tissue matrix destruction in TB patients, then inhibiting MMP-1 should prevent cavities ( Figure 3C ). Cipemastat is a potent inhibitor of MMP-1 and was originally developed by the Roche Corporation as an antiarthritis agent [28, 29] . We first confirmed that cipemastat did not have intrinsic antimycobacterial properties which our stock of cipemastat was able to inhibit MMP-1 in vitro (Supplementary Table 1 and Supplementary Figure 4) . Next, we conducted a 3-rabbit pharmacokinetic study to confirm that cipemastat was orally bioavailable in rabbits and had suitable kinetics for a daily dosing regimen (Table 1) . During the PK study, rabbits were given a single oral dose of cipemastat at a concentration of 100 mg/kg of body weight, a dose that was shown to be within the tolerability and efficacy range in human and animal studies [35, 36] . The results of the PK study showed an AUC 0-24 h of 21.79 h × μg/mL (49.9 μM × h), consistent with previously published oral dosing studies (Table 1) [35, 36] . Importantly, we found that the plasma concentration remained above the published half maximal inhibitory concentration (IC 50 ) of 26 ng/mL (60 nM) for 22 of 24 hours following a single oral dose (Table 1 and Supplementary  Figure 3 ) [28] . These results suggest that cipemastat shows good oral bioavailability in rabbits and confirms that a daily dosing regimen is sufficient to maintain plasma concentration levels above the IC 50 during most of a 24-hour period.
Cipemastat Monotherapy Did Not Protect Against Extensive Lung
Destruction and Cavitation
We randomized 18 rabbits into an 8-rabbit vehicle group and a 10-rabbit cipemastat group. All rabbits received 1 mL of PediaSure per kilogram of body weight. Rabbits in the cipemastat group received 100 mg/kg of cipemastat in PediaSure, the same dose that was validated during our PK study. Cipemastat was given orally from study weeks 5 through 10. This treatment window was consistent with the 4 weeks preceding the maximum frequency of cavitation and the time during which we predict that pathologic lesions will undergo matrix depletion ( Figure 5 ). Our results are based on 6 control-group rabbits and 7 cipemastat-treated rabbits.
During weeks 7, 9, 12, and 14, we performed breath-hold CT scans on all study rabbits. These CT scans revealed no difference in the number of cavities or severity of cavitation between the control and treatment groups throughout the study ( Figure 6A and 6B and Supplementary Figure 4) . We did notice a repeated trend toward worse cavitary disease among rabbits in the cipemastat-treated group. The animals were sacrificed during week 14 and the lungs were fixed and scored for disease severity by 2 independent blinded observers ( Figure 6C ). We also quantified the extent of disease within the lungs by cutting the lungs in the transverse plane and reporting the overall percentage of all lung slices with grossly visible disease ( Figure 6C ). Neither severity scoring nor disease quantification showed a difference between experimental groups.
Collagen Content at Cavity Walls Was Not Changed by Cipemastat
Treatment
Tuberculosis lung lesions are often encircled by a fibrotic wall [21] . This pathologic matrix deposition is also a feature of rabbits modeling cavitary TB (Figures 3B and 6D) . Because cipemastat inhibits collagenase activity, we predicted that cipemastat administration Figure 5 . Experimental overview to investigate the pharmacologic inhibition of tissue destruction and cavitation using cipemastat in rabbits infected with Mycobacterium tuberculosis. The predicated temporal window for cavitation was designed based on data presented in Figure 2 . Abbreviations: CT, computed tomography; F, female; M, male; PK, pharmacokinetic.
should increase the collagen content around TB lesions. We used hue-thresholding to quantify the amount of collagen identified in blue by applying Masson's trichrome stain to formalin-fixed, paraffin-embedded lung sections of cavities ( Figure 6D ). Using this method, we were unable to identify any difference in the collagenous content of cavity walls, suggesting that cipemastat treatment did not change the phenotype of pathologic collagen accumulation around cavities in the rabbit model ( Figure 6D ).
DISCUSSION
We have developed a novel model for cavitary TB based on repetitive aerosol exposure to virulent M. tuberculosis. Our data show that repetitive exposure over a 2-week period produced more advanced disease and more cavities than a single exposure, even when we carefully adjusted the concentrations bacteria in the aerosol inoculum to provide the same total exposure between groups. This finding suggests a link between repetitive exposure and TB exacerbation and is further supported by recent epidemiological evidence that multiple exposures to infected contacts increases the risk of TB progression [27] . An association between repetitive exposure and severe TB may have important implications for epidemiology and infection control in high-incidence regions of the world [37] . Our experiments did not evaluate the mechanism of repetitive exposure-related disease exacerbation; however, it is likely that the driver of more severe disease in repeatedly exposed animals is repeated priming of cell-mediated immunity. Although untested, repetitive exposure may cause a cascading set of T-cell priming and expansion events that disproportionately exacerbate the immune response against M. tuberculosis antigen in the lung [38] .
Our data show that modeling cavitary TB by repetitive aerosol exposure also models a spectrum of human lesions and pathologic matrix depletion associated with caseous and cavitary pulmonary TB [39] . We took advantage of this model to screen cipemastat, a potent and specific MMP-1 inhibitor, as an inhibitor of cavitation [28] . Our study was supported by a molecular phenotype in which MMP-1 expression increased around tuberculous lesions with matrix destruction [19] . In these experiments, we administered cipemastat for 4 weeks preceding the development of caseous and cavitary lesions in the repetitive aerosol model. However, our results did not show a reduction in cavitation or disease severity.
As part of our investigations, we confirmed that the plasma concentrations of cipemastat were well above the IC 50 during the 24-hour dosing cycle. We did not sample the concentration of cipemastat in TB lesions, so it is possible that cipemastat did not reach inhibitory concentrations within granulomas undergoing matrix destruction. Furthermore, MMP activity may be highly localized in pericellular niches [40] . Alternatively, MMP-1 may act in conjunction with other extracellular collagenases to drive matrix depletion, and the inactivation of MMP-1 did not appreciably change the dynamics of cavity formation, reflecting redundancy in the proteolytic cascade. Finally, it is possible that MMP-1 is not a mediator of matrix depletion and cavitation. The increased expression of MMP-1 at TB lesions may be purely associative or indicate another role for MMP-1 in the pathobiology of TB.
Our results demonstrate an entirely new system to study TB cavities. We show that repetitive exposure to aerosolized M. tuberculosis produces a pathologically relevant phenotype for screening preclinical agents toward the prevention and treatment of cavity formation.
Supplementary Data
Supplementary materials are available at The Journal of Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.
Notes
Author contributions. M. E. U.: study design, data collection, data analysis, data interpretation, literature search, generation of figures, writing of manuscript, review and editing of manuscript. E. A. I.: study design, data collection, data analysis, data interpretation, literature search, generation of figures, writing of manuscript, review and editing of manuscript. K. B.: data analysis, data interpretation, generation of figures, review and editing of manuscript. A. K.: conceptualization of hypotheses, study design, interpretation of data, review and editing of manuscript. P. T. E.: conceptualization of hypotheses, study design, data interpretation, review and editing of manuscript. W. R. B.: conceptualization of hypotheses, study design, data interpretation, literature search, review and editing of manuscript, resources to support project.
